Pulmonx Corp. (LUNG)

Q: What's priced into Pulmonx Corp. (LUNG) stock?

The current valuation suggests that LUNG is priced cheaply compared to its peers, with a notable expectations gap. The market appears to have factored in some fragility, but overall, the valuation remains justified given the company's recent performance. This is a descriptive monitoring read, not investment advice.

Q: What does the Pulmonx Corp. (LUNG) outlook hinge on?

The thesis hinges on management's ability to return to year-over-year revenue growth and the overall performance of the healthcare sector. Key triggers include potential guidance cuts and the performance of sector bellwethers, which could influence sentiment and expectations. This is a descriptive monitoring read, not investment advice.

NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09

$1.98-4.81%

Close 2026-09-09 · 1-day change

Standing thesis

The standing, falsifiable read: what has to stay true, and what would break it.

Turnaround

Intact: The reason to own it still holds.

The bull case

Pulmonx aims to keep its gross margin at 75% in 2026. Revenue is expected to grow to about $91 million. The company is managing costs around $115 million. Recent earnings beats show some operational progress.

The bear case

Pulmonx is still loss-making with negative free cash flow of $23 million expected in 2026. Operating expenses remain high, pressuring profitability. Revenue growth may not be enough to offset costs and losses.

What's priced in

The market expects about 7% revenue growth and values the stock near $9.73. Our fair value is close at $9.92, reflecting justified growth but ongoing losses. We differ by emphasizing the risk from continued negative cash flow.

What has to stay true

Maintain gross margin at 75% for 2026Intact
Marginprimary75% · FY26 (guidance)
Breaks if: Gross margin falls below 70% in FY26
Keep operating expenses under $115M for 2026Intact
Capital Allocationprimary<= $115M · FY26 (guidance)
Breaks if: Operating expenses exceed $120M in FY26
Achieve revenue between $90M and $92M in 2026Intact
Revenue Growthprimary$90M to $92M · FY26 (guidance)
Breaks if: Revenue falls below $85M in FY26

Source: QuarterlyIQ research model· Written 2026-07-08· Health checked 2026-09-09· Version 1· Status: Intact· Reviewed when the evidence changes

This is not a price target or investment advice.

Current Outlook

Week of Sep 5, 2026

A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.

LUNG's long-term thesis reflects mixed financial performance amidst a supportive sector backdrop.

What kind of bet this is

This investment represents a speculative growth opportunity. The company is currently loss-making, but management is focused on driving revenue growth and controlling costs, which adds a layer of uncertainty to the thesis.

What's priced into Pulmonx Corp. (LUNG)

The current valuation suggests that LUNG is priced cheaply compared to its peers, with a notable expectations gap. The market appears to have factored in some fragility, but overall, the valuation remains justified given the company's recent performance.

What the fundamentals likely do

Management has shown mixed results in achieving revenue growth, with recent declines in revenue. However, they have successfully improved gross margins and reduced operating expenses, indicating some positive operational progress.

What Pulmonx Corp. (LUNG) hinges on

The thesis hinges on management's ability to return to year-over-year revenue growth and the overall performance of the healthcare sector. Key triggers include potential guidance cuts and the performance of sector bellwethers, which could influence sentiment and expectations.

What changed in the latest read

What changed

The most important moves since the prior daily snapshot.

Short-term · Daily

No material changes since the prior snapshot.

Yes, our read has strengthened. The latest earnings report showed a positive surprise. This beat indicates that the company's recent financial performance remains solid within its industry. There are no new threats impacting the thesis at this time.

as of 2026-09-09

See upcoming information that could change the risk

Review the evidence to watch, what would become a concern, and what would make it less concerning.

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.